What’s Ahead for Core Laboratories N.V. (CLB) After Achieving 52-Week Low?

Core Laboratories N.V. (NYSE:CLB) Logo

Investors sentiment decreased to 0.71 in 2018 Q4. Its down 0.34, from 1.05 in 2018Q3. It fall, as 55 investors sold Core Laboratories N.V. shares while 104 reduced holdings. 37 funds opened positions while 76 raised stakes. 47.68 million shares or 0.41% less from 47.88 million shares in 2018Q3 were reported.
Aqr Management Lc owns 20,709 shares. Smithfield Trust Com holds 0.01% or 954 shares. Select Equity Lp has invested 0% in Core Laboratories N.V. (NYSE:CLB). Gotham Asset Mgmt Llc invested 0.01% in Core Laboratories N.V. (NYSE:CLB). Lazard Asset Mngmt Ltd Co holds 0.05% or 387,880 shares. Axa has invested 0.01% in Core Laboratories N.V. (NYSE:CLB). Captrust Financial Advisors stated it has 0.01% in Core Laboratories N.V. (NYSE:CLB). Ftb Advsrs holds 0% in Core Laboratories N.V. (NYSE:CLB) or 20 shares. Fisher Asset Mngmt Limited Liability Corporation reported 0.06% in Core Laboratories N.V. (NYSE:CLB). 2.61 million were accumulated by Massachusetts Fincl Ma. Bessemer Grp Inc Incorporated holds 0% of its portfolio in Core Laboratories N.V. (NYSE:CLB) for 9,895 shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Core Laboratories N.V. (NYSE:CLB) for 2,850 shares. Oppenheimer Inc has 28,297 shares for 0.05% of their portfolio. Timessquare Cap Mgmt Ltd Liability Corp reported 0.1% stake. Tower Rech Limited Liability Com (Trc) holds 6,169 shares.

The stock of Core Laboratories N.V. (NYSE:CLB) hit a new 52-week low and has $49.27 target or 9.00 % below today’s $54.14 share price. The 6 months bearish chart indicates high risk for the $2.40B company. The 1-year low was reported on May, 17 by Barchart.com. If the $49.27 price target is reached, the company will be worth $216.09 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 3.10% or $1.73 during the last trading session, reaching $54.14. About 239,467 shares traded. Core Laboratories N.V. (NYSE:CLB) has declined 35.41% since May 17, 2018 and is downtrending. It has underperformed by 39.78% the S&P500.

Analysts await Core Laboratories N.V. (NYSE:CLB) to report earnings on July, 24. They expect $0.46 EPS, down 22.03 % or $0.13 from last year’s $0.59 per share. CLB’s profit will be $20.40M for 29.42 P/E if the $0.46 EPS becomes a reality. After $0.44 actual EPS reported by Core Laboratories N.V. for the previous quarter, Wall Street now forecasts 4.55 % EPS growth.

Core Laboratories N.V. (NYSE:CLB) Ratings Coverage

Among 3 analysts covering Core Laboratories (NYSE:CLB), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Core Laboratories had 7 analyst reports since December 11, 2018 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, December 11 by JP Morgan. Credit Suisse downgraded the shares of CLB in report on Wednesday, December 19 to “Neutral” rating. The firm has “Neutral” rating given on Friday, January 4 by Citigroup.

More notable recent Core Laboratories N.V. (NYSE:CLB) news were published by: Foxbusiness.com which released: “The Oil Industry’s Data Revolution – Fox Business” on May 11, 2019, also Nasdaq.com with their article: “Energy Sector Update for 04/25/2019: CVI,HP,MMLP,CLB – Nasdaq” published on April 25, 2019, Finance.Yahoo.com published: “Did Hedge Funds Drop The Ball On Cyberark Software Ltd (CYBR)? – Yahoo Finance” on April 29, 2019. More interesting news about Core Laboratories N.V. (NYSE:CLB) were released by: Fool.com and their article: “3 Top Oil Stocks to Buy This Month – Motley Fool” published on February 26, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Core Laboratories (NYSE:CLB) Share Price Is Down 64% So Some Shareholders Are Wishing They Sold – Yahoo Finance” with publication date: May 10, 2019.

Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services to the gas and oil industry in the United States, Canada, and internationally. The company has market cap of $2.40 billion. It operates through three divisions: Reservoir Description, Production Enhancement, and Reservoir Management. It has a 25 P/E ratio. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples.

Core Laboratories N.V. (NYSE:CLB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.